Lilly's Q2 sales nudge up on animal health acquisition; Zoetis declares Q3 dividend; Scynexis offloads animal health CRO to Vista;

> Eli Lilly ($LLY) announced that its second-quarter revenues grew 1% year-over-year to nearly $5 billion, largely thanks to its acquisition of Novartis ($NVS) Animal Health. Release

> Zoetis ($ZTS) declared a third-quarter dividend of $0.083 a share, payable September 1. Release

> Scynexis ($SCYX) has sold its contract research and development business, which includes a screening platform used by animal health businesses, to Vista Pharma Solutions. Release

> Distributor Henry Schein ($HSIC) promoted Peter McCarthy, former head of its overseas animal health business, to president of Henry Schein Global Animal Health Group. Release

> Generic animal drugmaker Putney has hired Gary Eaton, formerly of IDEXX ($IDXX) as vice president of sales and marketing. Release

> The FDA announced that Moses Lake Professional Pharmacy in Washington is voluntarily recalling all unexpired human and veterinary drugs due to sterility concerns. Release

> The Steele Foundation awarded a 45-acre ranch in Cornville, AZ, to the University of Arizona, which plans to use the property for a proposed veterinary school. Story

> Colorado State University received $10 million from the Helen K. and Arthur E. Johnson Foundation to build an equine teaching hospital for veterinarians specializing in horse medicine. Article

> Australia's National Veterinary Care, a network of veterinary clinics, announced plans to raise $31 million in an initial public offering on the Australian Securities Exchange. Release

> VetStem Biopharma has inked a long-term partnership with VCA ($WOOF) Emergency Animal Hospital & Referral Center to provide stem cell treatments to pet owners in San Diego. Release

> The Natural Dog Company is recalling bags of its Tremenda Sticks dog chews due to potential Salmonella contamination. Release


Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…